Dae Gwin Jeong

Dr. Dae Gwin Jeong

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2016 in Toxins
Verified
Journal Article
Open access
PDF file
MLMoo-Seung Lee
Moo-Seung Lee
SKSunwoo Koo
Sunwoo Koo
DJDae Gwin Jeong
Dae Gwin Jeong
Vernon L.  TeshVernon L. Tesh
Vernon L. Tesh
Shiga toxins (Stxs) produced by Shiga toxin-producing bacteria Shigella dysenteriae serotype 1 and select serotypes of Escherichia coli are primary virulence factors in the pathogenesis of hemorrhagic colitis progressing to potentially fatal systemic complications, such as hemolytic uremic syndrome and central nervous system abnormalities. Current therapeutic options to treat patients infected with toxin-producing bacteria are limited. The structures of Stxs, toxin-receptor binding, intracellular transport and the mode of action of the toxins have been well defined. However, in the last decade, numerous studies have demonstrated that in addition to being potent protein synthesis inhibitors, Stxs are also multifunctional proteins capable of activating multiple cell stress signaling pathways, which may result in apoptosis, autophagy or activation of the innate immune response. Here, we briefly present the current understanding of Stx-activated signaling pathways and provide a concise review of therapeutic applications to target tumors by engineering the toxins.

20 February 2017 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
JNJi Yeong Noh
Ji Yeong Noh
SYSun-Woo Yoon
Sun-Woo Yoon
DKDoo-Jin Kim
Doo-Jin Kim
MLMoo-Seung Lee
Moo-Seung Lee
JKJi-Hyung Kim
Ji-Hyung Kim
HKHye Kwon Kim
Hye Kwon Kim

23 May 2016 in Transboundary and Emerging Diseases
Verified
Journal Article
Closed access
PDF file
HKH. K. Kim
H. K. Kim
SYS.-W. Yoon
S.-W. Yoon
DKD.-J. Kim
D.-J. Kim
BKB.-S. Koo
B.-S. Koo
JNJ. Y. Noh
J. Y. Noh
DJDae Gwin Jeong
Dae Gwin Jeong

22 January 2024 in Emerging Microbes & Infections
Verified
Journal Article
Open access
KLKyungmoon Lee
Kyungmoon Lee
MYMinjoo Yeom
Minjoo Yeom
HVHang Thi Thu Vu
Hang Thi Thu Vu
QHQuynh Do hai
Quynh Do hai
WNWoonsung Na
Woonsung Na
DSDaesub Song
Daesub Song

22 September 2024 in Emerging Microbes & Infections
Verified
Journal Article
Open access
KLKyungmoon Lee
Kyungmoon Lee
HVHang Thi Thu Vu
Hang Thi Thu Vu
MYMinjoo Yeom
Minjoo Yeom
DNDung Nguyễn
Dung Nguyễn
TTThi Tam Than
Thi Tam Than
DSDaesub Song
Daesub Song
African swine fever virus (ASFV) recombinant strains pose new challenges for diagnosis and control. This study characterizes genotype I and II recombinant ASFV strains identified in northern Vietnam in 2023 through whole-genome sequencing and comparative genomic analysis. Seven ASFV-positive samples from six provinces were analyzed, with recombinant strains detected in Bac Giang, Phu Tho, and Vinh Phuc provinces. Isolates showed hemadsorption positivity despite having genotype I B646L, indicating their recombinant nature. Genome-wide analysis revealed 19 recombination breakpoints consistent with Chinese recombinant strains. Vietnamese isolates shared 99.86-99.98% nucleotide identity with Chinese recombinants, forming a distinct monophyletic group. Comparative analysis identified 50 SNPs and INDELs, with 39 variations found across Vietnamese strains, distinguishing them from Chinese isolates. Unique genetic markers in C962R, I329L, and MGF 505-11L genes distinguished Vietnamese recombinants from Chinese counterparts, while mutations in C122R and NP1450L differentiated all recombinants from parental genotypes. The central variable region (CVR) of the B602L gene showed diversity among Vietnamese isolates, while the I73R-I329L intergenic regions were recognized as in the IGR2 group. This study enhances understanding of recombinant ASFV evolution through homologous recombination and identifies new genetic markers for improved detection and characterization. The observed genetic diversity highlights challenges for existing diagnostic methods and vaccine development, emphasizing the need for continued surveillance and research into the functional implications of these genetic variations on ASFV pathogenicity and transmissibility.

5 May 2022 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
JPJoung Ha Park
Joung Ha Park
MCMin Jae Cha
Min Jae Cha
HCHyewon Choi
Hyewon Choi
MKMin-Chul Kim
Min-Chul Kim
JCJin-Won Chung
Jin-Won Chung
Seong-Ho ChoiSeong-Ho Choi
Seong-Ho Choi
It remains unclear whether high titers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies aggravate clinical manifestations in patients or whether severe clinical manifestations result in high antibody titers. Thus, we investigated the cause–effect relationship between SARS-CoV-2 antibody titers and disease severity. We prospectively enrolled patients admitted with the diagnosis of coronavirus disease-19 (COVID-19) from February 2020 to August 2020. We measured SARS-CoV-2 antibody titers, namely anti-receptor-binding domain (RBD) antibody and neutralizing antibody (NAb), from blood samples and calculated the chest radiograph (CXR) scores of the patients to evaluate the severity of COVID-19. Overall, 40 patients with COVID-19 were enrolled. Pneumonia was observed in more than half of the patients (25/40, 60%). SARS-CoV-2 antibody titers were higher in patients who were aged >60 years (anti-RBD antibodies, P = 0.003 and NAb, P = 0.009), presented with pneumonia (P = 0.006 and 0.007, respectively), and required oxygen therapy (P = 0.003 and 0.004, respectively) than in those who were not. CXR scores peaked (at 15–21 days after the onset of symptoms) statistically significantly earlier than SARS-CoV-2 antibody titers (at 22–30 days for NAb and at 31–70 days for anti-RBD antibody). There was a close correlation between the maximum CXR score and the maximum SAR-CoV-2 antibody titer. Based on the comparison of the peak time of SARS-CoV-2 antibody titers with the CXR score after symptom onset, we suggest that severe clinical manifestations result in high titers of SARS-CoV-2 antibodies.